Literature DB >> 9218736

Relationship between folate-binding protein expression and cisplatin sensitivity in ovarian carcinoma cell lines.

F Ottone1, S Miotti, C Bottini, M Bagnoli, P Perego, M I Colnaghi, S Ménard.   

Abstract

It has been suggested that sensitivity of ovarian carcinomas to cisplatin is in part related to an endogenous folate deficiency. In this work, we investigated whether overexpression of the folate-binding protein (FBP), a receptor involved in folate transport, might be associated with cisplatin sensitivity. The results obtained on a panel of ten ovarian carcinoma cell lines that overexpress different levels of the FBP showed a statistically significant relationship between FBP overexpression and cisplatin responsiveness, with the most sensitive cell lines expressing higher FBP levels on their membrane than the less sensitive ones. The relationship was observed both in cells growing in standard medium-containing high-folate concentrations (2.3 microM) and in cells adapted to growth in low-folate (20 nM) medium. Analysis of two cisplatin-resistant cell lines derived from the cisplatin-sensitive IGROV1 ovarian carcinoma cell line indicated that resistance was associated with a significant decrease in FBP expression. However, the receptor does not appear to be directly responsible for drug sensitivity per se as different cell lines transfected with FBP cDNA did not become more sensitive to the drug. Together, the data suggest the possible predictive value of FBP in ovarian carcinoma, as higher levels of expression can be indirectly but significantly associated with increased drug sensitivity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9218736      PMCID: PMC2223805          DOI: 10.1038/bjc.1997.339

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  40 in total

1.  Influence on immunoreactive folate-binding proteins of extracellular folate concentration in cultured human cells.

Authors:  M A Kane; P C Elwood; R M Portillo; A C Antony; V Najfeld; A Finley; S Waxman; J F Kolhouse
Journal:  J Clin Invest       Date:  1988-05       Impact factor: 14.808

2.  Mechanisms of cross-resistance to methotrexate and 5-fluorouracil in an A2780 human ovarian carcinoma cell subline resistant to cisplatin.

Authors:  E M Newman; Y Lu; M Kashani-Sabet; V Kesavan; K J Scanlon
Journal:  Biochem Pharmacol       Date:  1988-02-01       Impact factor: 5.858

3.  Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II).

Authors:  A Eastman; N Schulte
Journal:  Biochemistry       Date:  1988-06-28       Impact factor: 3.162

4.  Elevated expression of thymidylate synthase cycle genes in cisplatin-resistant human ovarian carcinoma A2780 cells.

Authors:  K J Scanlon; M Kashani-Sabet
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

5.  Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines.

Authors:  H Masuda; R F Ozols; G M Lai; A Fojo; M Rothenberg; T C Hamilton
Journal:  Cancer Res       Date:  1988-10-15       Impact factor: 12.701

6.  Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells.

Authors:  P A Andrews; M P Murphy; S B Howell
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

7.  Receptor-mediated folate accumulation is regulated by the cellular folate content.

Authors:  B A Kamen; A Capdevila
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

8.  Properties of amino acid transport systems in K562 cells sensitive and resistant to cis-diamminedichloroplatinum(II).

Authors:  S Shionoya; Y Lu; K J Scanlon
Journal:  Cancer Res       Date:  1986-07       Impact factor: 12.701

9.  Biochemical and molecular properties of cisplatin-resistant A2780 cells grown in folinic acid.

Authors:  Y Lu; J Han; K J Scanlon
Journal:  J Biol Chem       Date:  1988-04-05       Impact factor: 5.157

10.  Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity.

Authors:  S Miotti; S Canevari; S Ménard; D Mezzanzanica; G Porro; S M Pupa; M Regazzoni; E Tagliabue; M I Colnaghi
Journal:  Int J Cancer       Date:  1987-03-15       Impact factor: 7.396

View more
  6 in total

1.  The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity.

Authors:  JianMin Lin; Jared L Spidel; Christopher J Maddage; Katherine A Rybinski; Rina P Kennedy; Candice L M Krauthauser; Young Chul Park; Earl F Albone; Sara Jacob; Matthew T Goserud; Bryon P Martinez; Qimin Chao; Yuhong Zhou; Nicholas C Nicolaides; J Bradford Kline; Luigi Grasso
Journal:  Cancer Biol Ther       Date:  2013-08-28       Impact factor: 4.742

2.  Understanding Role of DNA Repair and Cytochrome p-450 Gene Polymorphisms in Cervical Cancer Patient Treated With Concomitant Chemoradiation.

Authors:  Mohammad Abbas; Vandana Singh Kushwaha; Kirti Srivastava; Monisha Banerjee
Journal:  Br J Biomed Sci       Date:  2022-02-24       Impact factor: 2.432

3.  Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha.

Authors:  Wolfgang Ebel; Eric L Routhier; Brian Foley; Sara Jacob; Jennifer M McDonough; Rina K Patel; Howard A Turchin; Qimin Chao; J Bradford Kline; Lloyd J Old; Martin D Phillips; Nicholas C Nicolaides; Philip M Sass; Luigi Grasso
Journal:  Cancer Immun       Date:  2007-03-09

4.  Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein.

Authors:  Britta Stordal; Marion Hamon; Victoria McEneaney; Sandra Roche; Jean-Pierre Gillet; John J O'Leary; Michael Gottesman; Martin Clynes
Journal:  PLoS One       Date:  2012-07-11       Impact factor: 3.240

Review 5.  Profile of vintafolide (EC145) and its use in the treatment of platinum-resistant ovarian cancer.

Authors:  Mathieu Luyckx; Raffaella Votino; Jean-Luc Squifflet; Jean-François Baurain
Journal:  Int J Womens Health       Date:  2014-03-31

6.  Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer.

Authors:  A A van Zweeden; C J van Groeningen; R J Honeywell; E Giovannetti; R Ruijter; C H Smorenburg; G Giaccone; H M W Verheul; G J Peters; Hans J van der Vliet
Journal:  Cancer Chemother Pharmacol       Date:  2018-04-25       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.